InvestorsHub Logo
Followers 19
Posts 1039
Boards Moderated 0
Alias Born 04/18/2018

Re: None

Thursday, 07/02/2020 11:04:26 AM

Thursday, July 02, 2020 11:04:26 AM

Post# of 35961
MediciNova has previously announced that a new patent application for Glioblastoma (Brain Cancer) included the possibility of including Mipsagargin as a combination therapy with their drug MN-166. Now it seems that MediciNova is jumping into the COVID-19 arena also with the same MN-166 drug.

MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) for Prevention of Acute Respiratory Distress Syndrome in Patients with COVID-19
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RBSH News